Why This Summit Is Unmissable for Pharma
Evaluate the Future of RNA-Targeted Small Molecules Before the Rest of the Industry
RNA-targeted small molecules are moving beyond scientific promise and into clinical reality.
As emerging biotechs generate increasingly compelling preclinical and clinical data, pharma companies are actively evaluating where to invest, partner, and build future pipelines. This summit provides direct access to the innovators shaping the next generation of RNA-targeted therapeutics.
Challenges We Help Solve
Determining Whether RNA-Targeted Small Molecules Are Ready for Broad Investment
Hear directly from organizations generating clinical and preclinical validation to assess where the modality is headed and where future opportunities exist.
Identifying the Most Promising Platforms & Partners
Evaluate emerging technologies, differentiated pipelines, and innovative biotech companies before they become widely recognized acquisition or partnership targets.
Understanding What Constitutes Clinical Readiness
Gain insight into the efficacy, safety, selectivity, and translational evidence required to support future licensing and investment decisions.
Assessing Which Modalities Will Win
Compare splice modulation, direct RNA binding, degraders, covalent binders, translation inhibition approaches, and epitranscriptomic strategies.
Exploring Future Commercial Opportunities
Understand where RNA-targeting could expand beyond oncology and neurodegenerative diseases into broader therapeutic applications.
Priority Sessions for Pharma Teams
Evaluating Clinical Momentum Across the RNA-Targeting Landscape
Conference Day One: REM-422, a MYB mRNA Degrader, in Recurrent/Metastatic Adenoid Cystic Carcinoma (ACC)
Speaker:
- Dominic Reynolds, Chief Scientific Officer, Remix Therapeutics
Assess one of the field's most advanced clinical programs and understand the emerging data helping to validate RNA-targeted small molecules as a therapeutic modality.
Understanding the Next Generation of RNA-Targeting Modalities
Conference Day Two: Advancing First-in-Class Condensate Modulators for Previously Inaccessible Targets
Speaker:
- Ann Boija, Senior Vice President, Head of Research, Dewpoint Therapeutics
Explore emerging approaches beyond splice modulation and assess how condensate biology could unlock previously inaccessible disease targets and future partnering opportunities.
Determining the Future Commercial Potential of RNA Targeting
Conference Day Two: Panel Discussion: Establishing RNA-Targeted Small Molecules as a Generalizable Drug Modality
Speakers:
- Yann Foricher, Sanofi
- Tom Chappie, Pfizer
- Nikolai Naryshkin, Ribonaut Therapeutics
- Dominic Reynolds, Remix Therapeutics
Hear industry leaders debate the evidence, technologies, disease areas, and translational milestones required to establish RNA targeting as the next major drug discovery modality.
Benchmark Your Strategy Against Peers
Questions you could ask your peers to benchmark against them:
Which companies are generating the strongest clinical validation?
What therapeutic areas beyond oncology and neurodegeneration are emerging?
Where are biotech companies seeking development or commercial partners?
Which platforms appear most scalable?
How are competitors evaluating RNA-targeting investments?
What Past Attendees Say
As RNA-targeted drug discovery transitions from emerging science to validated therapeutic strategy, this summit provides the essential ecosystem for collaboration and knowledge exchange. Engaging with fellow innovators allows us to collectively address the field's challenges, explore new frontiers, and build partnerships that will define the next generation of medicines. In 2026 for my 8th attendance, I will be again thrilled to engage & exchange with my scientific peers of this booming field.
The RNA conference provides the best opportunity to engage with the largest number of RNA-targeting companies, most of whom attend other conferences but rarely the same ones.
Explore the Agenda
Hear the latest industry advances in RNA target selection, structure-guided design, selective modulation and translational strategies across the full RNA-targeted small molecule pipeline and during our packed agenda, interactive roundtables, and panel discussions.
Partner With Us
Position yourself alongside other leading solution providers to ensure your brand is at the heart of biopharma deals.
Join Biopharma Experts
Connect with RNA-targeted small molecule leaders across discovery, preclinical and clinical development during our dedicated networking sessions to exchange insights, build collaborations and strengthen decisions from target selection to therapeutic impact.